C L Shapiro|D F Hayes - JoVE Visualize

Showing results (51-60 of 121) with videos related to

Pageof 13

Sort By:

Cancer Research|May 19, 2001

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibodyC Akewanlop, M Watanabe, B Singh, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2005

Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patientsE Mrózek, C A Rhoades, J Allen, et al.

Breast Cancer Research and Treatment|June 16, 1999

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210M Watanabe, P K Wallace, T Keler, et al.

Breast Cancer Research and Treatment|November 26, 1999

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancerS Pyrhönen, J Ellmén, J Vuorinen, et al.

Journal of the National Cancer Institute|March 2, 1994

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancersM Nguyen, H Watanabe, A E Budson, et al.

Angiology|June 1, 1984

Takayasu's arteritis of the upper extremities. A case report and review of literatureS Al-Awami, D A Katz, M F Kreifels, et al.

Cancer|September 15, 1990

Comprehensive management of disseminated breast cancerI C Henderson, J E Garber, J B Breitmeyer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)E Mrozek, J Kolesar, D Young, et al.

Cancer|January 10, 2001

Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinomaA F Jacobson, C L Shapiro, A D Van den Abbeele, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu proteinH Yamauchi, A O'Neill, R Gelman, et al.

Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:

Pageof 13

Cancer Research|May 19, 2001

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibodyC Akewanlop, M Watanabe, B Singh, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2005

Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patientsE Mrózek, C A Rhoades, J Allen, et al.

Breast Cancer Research and Treatment|June 16, 1999

Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210M Watanabe, P K Wallace, T Keler, et al.

Breast Cancer Research and Treatment|November 26, 1999

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancerS Pyrhönen, J Ellmén, J Vuorinen, et al.

Journal of the National Cancer Institute|March 2, 1994

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancersM Nguyen, H Watanabe, A E Budson, et al.

Angiology|June 1, 1984

Takayasu's arteritis of the upper extremities. A case report and review of literatureS Al-Awami, D A Katz, M F Kreifels, et al.

Cancer|September 15, 1990

Comprehensive management of disseminated breast cancerI C Henderson, J E Garber, J B Breitmeyer, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)E Mrozek, J Kolesar, D Young, et al.

Cancer|January 10, 2001

Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinomaA F Jacobson, C L Shapiro, A D Van den Abbeele, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu proteinH Yamauchi, A O'Neill, R Gelman, et al.

Pageof 13